← Back to directory

Hiroaki Shimokawa

Researcher Next ID · RN-022364

Researcher · Medicine

Toho University

Tokyo, Japan

Not currently recruitingFunding unknown
Works count
1,687
Citation count
72,012
H-index
127
i10-index
663

Research interests

Medicine
Nitric Oxide and Endothelin Effects
Cardiac Imaging and Diagnostics
Cardiovascular Function and Risk Factors
Pulmonary Hypertension Research and Treatments
Heart Failure Treatment and Management

Publications

  • JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure ― Digest Version ―

    Circulation Journal · 2019 · https://doi.org/10.1253/circj.cj-19-0342

  • JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome

    Circulation Journal · 2019 · 10.1253/circj.cj-19-0133

  • International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology

    European Heart Journal · 2018 · https://doi.org/10.1093/eurheartj/ehy076

  • International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management

    European Heart Journal · 2018 · https://doi.org/10.1093/eurheartj/ehy077

  • Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)

    European Heart Journal · 2018 · 10.1093/eurheartj/ehy310

  • Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

    The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)32247-x

  • International standardization of diagnostic criteria for microvascular angina

    International Journal of Cardiology · 2017 · 10.1016/j.ijcard.2017.08.068

  • Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

    The Lancet · 2017 · 10.1016/s0140-6736(17)32814-3

  • Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

    New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1707914

  • Endothelial Functions

    Arteriosclerosis Thrombosis and Vascular Biology · 2017 · 10.1161/atvbaha.117.309813

  • RhoA/Rho-Kinase in the Cardiovascular System

    Circulation Research · 2016 · 10.1161/circresaha.115.306532

  • Endothelial dysfunction and vascular disease - a 30th anniversary update

    Acta Physiologica · 2015 · https://doi.org/10.1111/apha.12646

  • Heart Failure as a General Pandemic in Asia

    European Journal of Heart Failure · 2015 · 10.1002/ejhf.319

  • International standardization of diagnostic criteria for vasospastic angina

    European Heart Journal · 2015 · 10.1093/eurheartj/ehv351

  • Heart Failure: Preventing Disease and Death Worldwide

    ESC Heart Failure · 2014 · https://doi.org/10.1002/ehf2.12005

  • Impaired Insulin Signaling in Endothelial Cells Reduces Insulin-Induced Glucose Uptake by Skeletal Muscle

    Cell Metabolism · 2011 · 10.1016/j.cmet.2011.01.018

  • Endothelial dysfunction and vascular disease

    Acta Physiologica · 2009 · 10.1111/j.1748-1716.2009.01964.x

  • Rho-Kinase Is an Important Therapeutic Target in Cardiovascular Medicine

    Arteriosclerosis Thrombosis and Vascular Biology · 2005 · 10.1161/01.atv.0000176193.83629.c8

  • Long-Term Inhibition of Rho-Kinase Suppresses Angiotensin II–Induced Cardiovascular Hypertrophy in Rats In Vivo

    Circulation Research · 2003 · 10.1161/01.res.0000096650.91688.28

  • Suppression of Coronary Artery Spasm by the Rho-Kinase Inhibitor Fasudil in Patients With Vasospastic Angina

    Circulation · 2002 · 10.1161/hc1002.105938

  • Rho-Kinase Mediates Hypoxia-Induced Downregulation of Endothelial Nitric Oxide Synthase

    Circulation · 2002 · 10.1161/01.cir.0000020682.73694.ab

  • Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice

    Journal of Clinical Investigation · 2000 · 10.1172/jci10506

  • Primary Endothelial Dysfunction: Atherosclerosis

    Journal of Molecular and Cellular Cardiology · 1999 · 10.1006/jmcc.1998.0841

  • The Importance of the Hyperpolarizing Mechanism Increases as the Vessel Size Decreases in Endothelium-Dependent Relaxations in Rat Mesenteric Circulation

    Journal of Cardiovascular Pharmacology · 1996 · 10.1097/00005344-199611000-00014

  • Endothelium-derived relaxing factor and coronary vasospasm.

    Circulation · 1989 · 10.1161/01.cir.80.1.1

Current projects

    No projects listed.